129 related articles for article (PubMed ID: 17355186)
1. Engineering an improved cell cycle-regulatable herpes simplex virus type 1 amplicon vector with enhanced transgene expression in proliferating cells yet attenuated activities in resting cells.
Wang GY; Ho IA; Sia KC; Miao L; Hui KM; Lam PY
Hum Gene Ther; 2007 Mar; 18(3):222-31. PubMed ID: 17355186
[TBL] [Abstract][Full Text] [Related]
2. Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector.
Ho IA; Hui KM; Lam PY
Hum Gene Ther; 2004 May; 15(5):495-508. PubMed ID: 15144579
[TBL] [Abstract][Full Text] [Related]
3. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas.
Lam PY; Sia KC; Khong JH; De Geest B; Lim KS; Ho IA; Wang GY; Miao LV; Huynh H; Hui KM
Mol Ther; 2007 Jun; 15(6):1129-36. PubMed ID: 17426711
[TBL] [Abstract][Full Text] [Related]
4. CDF-1, a novel E2F-unrelated factor, interacts with cell cycle-regulated repressor elements in multiple promoters.
Liu N; Lucibello FC; Körner K; Wolfraim LA; Zwicker J; Müller R
Nucleic Acids Res; 1997 Dec; 25(24):4915-20. PubMed ID: 9396796
[TBL] [Abstract][Full Text] [Related]
5. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.
Miao L; Fraefel C; Sia KC; Newman JP; Mohamed-Bashir SA; Ng WH; Lam PY
Br J Cancer; 2014 Jan; 110(1):94-106. PubMed ID: 24196790
[TBL] [Abstract][Full Text] [Related]
6. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells.
Xu Y; Fang F; Ludewig G; Jones G; Jones D
DNA Cell Biol; 2004 Jul; 23(7):419-29. PubMed ID: 15294091
[TBL] [Abstract][Full Text] [Related]
7. Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin.
Suzuki M; Kasai K; Saeki Y
J Virol; 2006 Apr; 80(7):3293-300. PubMed ID: 16537596
[TBL] [Abstract][Full Text] [Related]
8. Three CCAAT-boxes and a single cell cycle genes homology region (CHR) are the major regulating sites for transcription from the human cyclin B2 promoter.
Wasner M; Haugwitz U; Reinhard W; Tschöp K; Spiesbach K; Lorenz J; Mössner J; Engeland K
Gene; 2003 Jul; 312():225-37. PubMed ID: 12909359
[TBL] [Abstract][Full Text] [Related]
9. CHF: a novel factor binding to cyclin A CHR corepressor element.
Philips A; Chambeyron S; Lamb N; Vié A; Blanchard JM
Oncogene; 1999 Nov; 18(46):6222-32. PubMed ID: 10597220
[TBL] [Abstract][Full Text] [Related]
10. Chimpanzee, orangutan, mouse, and human cell cycle promoters exempt CCAAT boxes and CHR elements from interspecies differences.
Müller GA; Heissig F; Engeland K
Mol Biol Evol; 2007 Mar; 24(3):814-26. PubMed ID: 17205977
[TBL] [Abstract][Full Text] [Related]
11. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression.
Li F; Altieri DC
Cancer Res; 1999 Jul; 59(13):3143-51. PubMed ID: 10397257
[TBL] [Abstract][Full Text] [Related]
12. A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control.
Nettelbeck DM; Jérôme V; Müller R
Gene Ther; 1999 Jul; 6(7):1276-81. PubMed ID: 10455436
[TBL] [Abstract][Full Text] [Related]
13. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells.
Xu Y; Fang F; Ludewig G; Jones G; Jones D
DNA Cell Biol; 2004 Sep; 23(9):527-37. PubMed ID: 15383173
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of transcriptional targeting strategy for human hepatocellular carcinoma in an orthotopic xenograft mouse model.
Sia KC; Huynh H; Chung AY; Ooi LL; Lim KH; Hui KM; Lam PY
Mol Cancer Ther; 2013 Aug; 12(8):1651-64. PubMed ID: 23720769
[TBL] [Abstract][Full Text] [Related]
15. Targeting proliferating tumor cells via the transcriptional control of therapeutic genes.
Ho IA; Hui KM; Lam PY
Cancer Gene Ther; 2006 Jan; 13(1):44-52. PubMed ID: 16037822
[TBL] [Abstract][Full Text] [Related]
16. Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA.
Sabbioni S; Callegari E; Manservigi M; Argnani R; Corallini A; Negrini M; Manservigi R
Gene Ther; 2007 Mar; 14(5):459-64. PubMed ID: 17051250
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
19. Polo-like kinase 4 transcription is activated via CRE and NRF1 elements, repressed by DREAM through CDE/CHR sites and deregulated by HPV E7 protein.
Fischer M; Quaas M; Wintsche A; Müller GA; Engeland K
Nucleic Acids Res; 2014 Jan; 42(1):163-80. PubMed ID: 24071582
[TBL] [Abstract][Full Text] [Related]
20. Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle.
Wang Y; Mukherjee S; Fraefel C; Breakefield XO; Allen PD
Hum Gene Ther; 2002 Jan; 13(2):261-73. PubMed ID: 11812282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
